Drug intelligence / Profile preview

ACT-541478

Development stage: Unknown
Lead developer: Idorsia
Modality: Small Molecules
Administration: Oral

Overview

ACT-541478 is an investigational small molecule agonist of the G protein-coupled receptor 139 (GPR139), developed by Idorsia Pharmaceuticals for the treatment of central nervous system (CNS) disorders. GPR139 is an orphan receptor primarily expressed in the habenula and the medial septum of the brain, regions associated with the regulation of mood, motivation, and cognitive functions. By targeting this receptor, ACT-541478 aims to modulate neuronal activity in these specific circuits. The compound has undergone Phase 1 clinical testing in healthy adult and elderly volunteers to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics following oral administration.

Targets

GPR139 (G protein-coupled receptor 139)

Beyond the preview

Go deeper on ACT-541478.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACT-541478.

Explore the full profile